290 related articles for article (PubMed ID: 9491919)
1. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
[TBL] [Abstract][Full Text] [Related]
2. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
[TBL] [Abstract][Full Text] [Related]
3. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
[TBL] [Abstract][Full Text] [Related]
4. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
5. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.
Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H
Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252
[TBL] [Abstract][Full Text] [Related]
6. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.
Stevens R; Howard KE; Nordone S; Burkhard M; Dean GA
J Virol; 2004 Aug; 78(15):8210-8. PubMed ID: 15254192
[TBL] [Abstract][Full Text] [Related]
7. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz H
J Am Vet Med Assoc; 1991 Nov; 199(10):1446-52. PubMed ID: 1666101
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
[TBL] [Abstract][Full Text] [Related]
10. FIV vaccine studies. II. Clinical findings, hematological changes and kinetics of blood lymphocyte subsets.
Hofmann-Lehmann R; Holznagel E; Aubert A; Bauer-Pham K; Lutz H
Vet Immunol Immunopathol; 1995 May; 46(1-2):115-25. PubMed ID: 7618251
[TBL] [Abstract][Full Text] [Related]
11. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
Leutenegger CM; Boretti FS; Mislin CN; Flynn JN; Schroff M; Habel A; Junghans C; Koenig-Merediz SA; Sigrist B; Aubert A; Pedersen NC; Wittig B; Lutz H
J Virol; 2000 Nov; 74(22):10447-57. PubMed ID: 11044089
[TBL] [Abstract][Full Text] [Related]
12. Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection.
Cuisinier AM; Meyer A; Chatrenet B; Verdier AS; Aubert A
Vaccine; 1999 Feb; 17(5):415-25. PubMed ID: 10073718
[TBL] [Abstract][Full Text] [Related]
13. Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus.
Tijhaar EJ; Huisman W; Huisman RC; Siebelink KH; Karlas JA; de Ronde A; van Herwijnen R; Mooi FR; Osterhaus AD
J Gen Virol; 1997 Dec; 78 ( Pt 12)():3265-75. PubMed ID: 9400977
[TBL] [Abstract][Full Text] [Related]
14. Mechanism(s) of FIV vaccine protection.
Pu R; Tellier MC; Yamamoto JK
Leukemia; 1997 Apr; 11 Suppl 3():98-101. PubMed ID: 9209311
[TBL] [Abstract][Full Text] [Related]
15. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
16. Experimental vaccine protection against feline immunodeficiency virus.
Yamamoto JK; Okuda T; Ackley CD; Louie H; Pembroke E; Zochlinski H; Munn RJ; Gardner MB
AIDS Res Hum Retroviruses; 1991 Nov; 7(11):911-22. PubMed ID: 1662057
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination and infection in cats.
Levy JK; Crawford PC; Kusuhara H; Motokawa K; Gemma T; Watanabe R; Arai S; Bienzle D; Hohdatsu T
J Vet Intern Med; 2008; 22(2):330-4. PubMed ID: 18371028
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats.
Huisman W; Schrauwen EJ; Pas SD; van Amerongen G; Rimmelzwaan GF; Osterhaus AD
Vaccine; 2008 May; 26(21):2553-61. PubMed ID: 18430494
[TBL] [Abstract][Full Text] [Related]
19. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus.
Finerty S; Stokes CR; Gruffydd-Jones TJ; Hillman TJ; Barr FJ; Harbour DA
Vaccine; 2001 Oct; 20(1-2):49-58. PubMed ID: 11567745
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
